The Oncura Story

On July 1, 2003, a merger between two innovative leaders in prostate cancer treatments set the standard for minimally invasive options. Amersham Health (now GE Healthcare)-Therapy Business, the leader in brachytherapy and Galil Medical’s Urology Business, the innovator in cryotherapy procedures was finalized. This formed a new company combining both our people and products enabling us to champion advances in minimally invasive prostate-cancer treatments. This new company is Oncura.

Oncura has a separate and distinct identity from its parent companies and is unique in its ability to offer prostate cancer specialists the two leading minimally invasive treatment options for prostate cancer – brachytherapy and cryotherapy. Having both options in our product portfolio enables us to better meet physicians' and patients' needs.

Our goal is to champion the appropriate use of brachytherapy and cryotherapy as the treatments of choice for prostate cancer. Brachytherapy has long-term data demonstrating clinical efficacy in treating early stage prostate cancer, while cryotherapy is a suitable minimally invasive treatment option for later-stage or radiation-failure patients. In addition, Oncura has the ability to offer cryotherapy as a minimally invasive option for urologists treating kidney cancer.

Oncura’s vision is to lead the market by providing minimally invasive prostate cancer treatment options and to expand our portfolio to include additional products along the prostate disease management continuum.

Forming Oncura exemplifies our ongoing commitment to innovations in minimally invasive prostate and kidney cancer care for patients and physicians.